Abstract
Previous studies have shown that the prognosis of patients who have tumours with high microvessel density (MVD) is worse than that of patients who have a lower density in a variety of cancers. In this study, we investigated the clinical relevance of neovascularity assessed by MVD and the concentration of vascular endothelial growth factor (VEGF) in the tumour tissue of patients with soft tissue sarcoma in comparison with major clinicohistologic parameters by univariate and multivariate analysis. In 115 patients with soft tissue sarcoma, MVD was measured by counting vessels stained with factor VIII antibody. The concentration of VEGF in the tumour tissue was determined by enzyme-linked immunosorbent assay. These parameters were then compared with disease outcome. The concentration of VEGF in the tumour tissue, but not MVD, was found to be correlated with disease outcome in patients with soft tissue, sarcoma. VEGF concentration in the tumour tissue showed a relationship with the clinical stage and histologic grade of the tumour. There was no significant difference in the levels of tissue VEGF concentration and MVD among soft tissue sarcomas classified according to histologic type. The level of tissue VEGF concentration in patients who had subsequent local recurrence and metastasis were significantly higher than the respective values in patients who did not have such disease outcome. No significant correlation existed between MVD and the concentration of VEGF in the tumour tissue. Univariate analysis showed that a high tissue VEGF concentration was associated with poor overall survival of the patient and a greater probability that local recurrence and metastasis had occurred. Multivariate analysis revealed that the tissue concentration of VEGF is an independent prognostic factor for the disease outcome of patients with soft tissue sarcoma. VEGF concentration in the tumour tissue, but not MVD, is an additional prognostic parameter for disease outcome in patients with soft tissue sarcoma, regardless of histologic type. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Berkman RA, Merrill MJ, Reinhold WC, Monacci WT and Saxena A (1993) Expression of vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Inves 91: 153-159
Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J and Barker PJ (1995) Expression of vascular endothelial growth factor and its receptor fit and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506–516
Borgstrom P, Hillan KJ, Sriramarao P and Ferrara N (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiogenesis therapy from intravital videomicroscopy. Cancer Res 56: 4031–4039
Brawer MK (1996) Quantitative microvessel density: a staging and prognostic marker for human prostatic carcinoma. Cancer 78: 345–349
Claffey KP, Brown LF, del Aguila LF, Tognazzi K and Yeo KT (1996) Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172–181
Coindre JM, Terrier P, Bui NB, Bonichon F, Colli F and Le Doussal V (1996) Prognostic factors in adults patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French federation of cancer centers sarcoma group. J Clin Oncol 14: 869–877
Folkman J (1986) How is blood vessel growth regulated in normal and neoplastic tissue?. Cancer Res 46: 467–473
Folkman J, Watson K, Ingber D and Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 338: 58–61
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4–6
Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P and Panizzoni GA (1996) Prognostic and predictive value of tumor angiogenesis in ovarian carcinomas. Int J Cancer 69: 205–211
Gaynor JJ, Tan CC, Casper ES, Collin CF and Friedrich C (1992) Refinement of clinicopathologic staging for localized aoft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 10: 1317–1329
Gimbrone MA, Leapman S, Cotran RS and Folkman J (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261–276
Gimbrone MA, Cotran RS, Leapman S and Folkman J (1974) Tumor growth neovascularization: an experimental model using rabbit cornea. J Natl Cancer Inst 52: 413–427
Hermanek P and Sobin LH (1992). UICC TNM Classification of malignant tumours, Berlin, Springer-Verlag
Liotta L, Kleinman J and Saldel G (1974) Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34: 997–1004
Liotta LA, Steeg PS and Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336
Maeda K, Chung Y-S, Takatsuka S, Ogawa Y and Sawada Y (1995) Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 13: 477–481
Maeda K, Chung Y-S, Ogawa Y, Takatsuka S and Kang S-M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858–863
Mandard AM, Petiot JF, Marnay J, Mandard JC and Chasle J (1989) Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer 63: 1437–1451
Miller JW, Adamis AP, Shima DT and D’Amore PA Moulton RS (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574–584
Presta LG, Chen H, O'Connor SJ, Chisholm V and Meng G (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for therapy for solid tumors and other disorders. Cancer Res 57: 4593–4599
Takabayashi Y, Akiyama S, Yamada K, Akiba S and Aikou T (1996) Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 78: 226–231
Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964–3968
Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD and Ellis LM (1996) Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 2: 1679–1684
Takano S, Yoshii Y, Kondo S, Suzuki H and Maruno T (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185–2190
Yamazaki K, Abe S, Takekawa H, Sudou N and Watanabe N (1994) Tumor angiogenesis in human lung adenocarcinoma. Cancer 74: 2245–2250
Yeo K, Wang HH, Nagy JA, Sioussat TM and Ledbetter SR (1993) Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53: 2912–2918
Zhang HT, Craft P, Scott PA, Ziche M, Weich HA, Harris AL and Bicknell R (1995) Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cell. J Natl Cancer Inst 87: 213–217
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Yudoh, K., Kanamori, M., Ohmori, K. et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84, 1610–1615 (2001). https://doi.org/10.1054/bjoc.2001.1837
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1837
Keywords
This article is cited by
-
Regorafenib for the Treatment of Sarcoma
Current Treatment Options in Oncology (2022)
-
Molecular mechanisms underpinning sarcomas and implications for current and future therapy
Signal Transduction and Targeted Therapy (2021)
-
Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma
BMC Cancer (2018)
-
Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
BMC Cancer (2015)
-
Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa)
World Journal of Surgical Oncology (2014)